EPCs and pathological angiogenesis: When good cells go bad

Sergio Li Calzi, Matthew B. Neu, Lynn C. Shaw, Jennifer L. Kielczewski, Nicanor I. Moldovan, Maria B. Grant

Research output: Contribution to journalArticle

80 Citations (Scopus)

Abstract

Bone-marrow-derived endothelial progenitor cells (EPCs) contribute to angiogenesis-mediated pathological neovascularization, and recent studies have begun to recognize the biological significance of this contribution. This review will discuss the ability of EPCs to contribute to neovascularization in both physiological and pathological conditions. Circulating EPCs were originally identified in 1997 by Asahara as CD34+ VEGFR2+ mononuclear cells. These cells differentiated into an endothelial phenotype, expressed endothelial markers, and incorporated into neovessels at sites of ischemia (Asahara et al., 1997). EPCs provide both instructive (release of pro-angiogenic cytokines) and structural (vessel incorporation and stabilization) functions that contribute to the initiation of neo-angiogenesis. EPC populations can be characterized based on surface markers of freshly isolated cells, or they can be described by their in vitro characteristics once placed in culture. However, a major stumbling block to progress in the field has been the lack of consensus among investigators as to the optimal characterization of EPCs. This review intends to address the role of both EPC classes and evaluate how they interact in the setting of pathological angiogenesis. Since the EPCs may be responsible for turning on the "angiogenic switch," strategies have been employed to keep this switch in the "off" position for diseases like cancer, retinopathy, and wet AMD. The expectation is that EPCs will evolve into clinically useful prognostic and predictive tools in cancer and in ocular diseases associated with pathological neovascularization and that targeting this cell type is a key to successful management of patients suffering from diseases associated with pathological neovascularization.

Original languageEnglish (US)
Pages (from-to)207-216
Number of pages10
JournalMicrovascular Research
Volume79
Issue number3
DOIs
StatePublished - May 2010
Externally publishedYes

Fingerprint

Pathologic Neovascularization
Endothelial cells
Eye Neoplasms
Switches
Endothelial Progenitor Cells
Eye Diseases
Bone
Ischemia
Stabilization
Bone Marrow
Research Personnel
Cytokines
Phenotype

Keywords

  • Diabetic retinopathy
  • Endothelial progenitor cells
  • Stem cells

ASJC Scopus subject areas

  • Biochemistry
  • Cardiology and Cardiovascular Medicine
  • Cell Biology

Cite this

Calzi, S. L., Neu, M. B., Shaw, L. C., Kielczewski, J. L., Moldovan, N. I., & Grant, M. B. (2010). EPCs and pathological angiogenesis: When good cells go bad. Microvascular Research, 79(3), 207-216. https://doi.org/10.1016/j.mvr.2010.02.011

EPCs and pathological angiogenesis : When good cells go bad. / Calzi, Sergio Li; Neu, Matthew B.; Shaw, Lynn C.; Kielczewski, Jennifer L.; Moldovan, Nicanor I.; Grant, Maria B.

In: Microvascular Research, Vol. 79, No. 3, 05.2010, p. 207-216.

Research output: Contribution to journalArticle

Calzi, SL, Neu, MB, Shaw, LC, Kielczewski, JL, Moldovan, NI & Grant, MB 2010, 'EPCs and pathological angiogenesis: When good cells go bad', Microvascular Research, vol. 79, no. 3, pp. 207-216. https://doi.org/10.1016/j.mvr.2010.02.011
Calzi SL, Neu MB, Shaw LC, Kielczewski JL, Moldovan NI, Grant MB. EPCs and pathological angiogenesis: When good cells go bad. Microvascular Research. 2010 May;79(3):207-216. https://doi.org/10.1016/j.mvr.2010.02.011
Calzi, Sergio Li ; Neu, Matthew B. ; Shaw, Lynn C. ; Kielczewski, Jennifer L. ; Moldovan, Nicanor I. ; Grant, Maria B. / EPCs and pathological angiogenesis : When good cells go bad. In: Microvascular Research. 2010 ; Vol. 79, No. 3. pp. 207-216.
@article{f114f09ae26b49d3891331bb719c456d,
title = "EPCs and pathological angiogenesis: When good cells go bad",
abstract = "Bone-marrow-derived endothelial progenitor cells (EPCs) contribute to angiogenesis-mediated pathological neovascularization, and recent studies have begun to recognize the biological significance of this contribution. This review will discuss the ability of EPCs to contribute to neovascularization in both physiological and pathological conditions. Circulating EPCs were originally identified in 1997 by Asahara as CD34+ VEGFR2+ mononuclear cells. These cells differentiated into an endothelial phenotype, expressed endothelial markers, and incorporated into neovessels at sites of ischemia (Asahara et al., 1997). EPCs provide both instructive (release of pro-angiogenic cytokines) and structural (vessel incorporation and stabilization) functions that contribute to the initiation of neo-angiogenesis. EPC populations can be characterized based on surface markers of freshly isolated cells, or they can be described by their in vitro characteristics once placed in culture. However, a major stumbling block to progress in the field has been the lack of consensus among investigators as to the optimal characterization of EPCs. This review intends to address the role of both EPC classes and evaluate how they interact in the setting of pathological angiogenesis. Since the EPCs may be responsible for turning on the {"}angiogenic switch,{"} strategies have been employed to keep this switch in the {"}off{"} position for diseases like cancer, retinopathy, and wet AMD. The expectation is that EPCs will evolve into clinically useful prognostic and predictive tools in cancer and in ocular diseases associated with pathological neovascularization and that targeting this cell type is a key to successful management of patients suffering from diseases associated with pathological neovascularization.",
keywords = "Diabetic retinopathy, Endothelial progenitor cells, Stem cells",
author = "Calzi, {Sergio Li} and Neu, {Matthew B.} and Shaw, {Lynn C.} and Kielczewski, {Jennifer L.} and Moldovan, {Nicanor I.} and Grant, {Maria B.}",
year = "2010",
month = "5",
doi = "10.1016/j.mvr.2010.02.011",
language = "English (US)",
volume = "79",
pages = "207--216",
journal = "Microvascular Research",
issn = "0026-2862",
publisher = "Academic Press Inc.",
number = "3",

}

TY - JOUR

T1 - EPCs and pathological angiogenesis

T2 - When good cells go bad

AU - Calzi, Sergio Li

AU - Neu, Matthew B.

AU - Shaw, Lynn C.

AU - Kielczewski, Jennifer L.

AU - Moldovan, Nicanor I.

AU - Grant, Maria B.

PY - 2010/5

Y1 - 2010/5

N2 - Bone-marrow-derived endothelial progenitor cells (EPCs) contribute to angiogenesis-mediated pathological neovascularization, and recent studies have begun to recognize the biological significance of this contribution. This review will discuss the ability of EPCs to contribute to neovascularization in both physiological and pathological conditions. Circulating EPCs were originally identified in 1997 by Asahara as CD34+ VEGFR2+ mononuclear cells. These cells differentiated into an endothelial phenotype, expressed endothelial markers, and incorporated into neovessels at sites of ischemia (Asahara et al., 1997). EPCs provide both instructive (release of pro-angiogenic cytokines) and structural (vessel incorporation and stabilization) functions that contribute to the initiation of neo-angiogenesis. EPC populations can be characterized based on surface markers of freshly isolated cells, or they can be described by their in vitro characteristics once placed in culture. However, a major stumbling block to progress in the field has been the lack of consensus among investigators as to the optimal characterization of EPCs. This review intends to address the role of both EPC classes and evaluate how they interact in the setting of pathological angiogenesis. Since the EPCs may be responsible for turning on the "angiogenic switch," strategies have been employed to keep this switch in the "off" position for diseases like cancer, retinopathy, and wet AMD. The expectation is that EPCs will evolve into clinically useful prognostic and predictive tools in cancer and in ocular diseases associated with pathological neovascularization and that targeting this cell type is a key to successful management of patients suffering from diseases associated with pathological neovascularization.

AB - Bone-marrow-derived endothelial progenitor cells (EPCs) contribute to angiogenesis-mediated pathological neovascularization, and recent studies have begun to recognize the biological significance of this contribution. This review will discuss the ability of EPCs to contribute to neovascularization in both physiological and pathological conditions. Circulating EPCs were originally identified in 1997 by Asahara as CD34+ VEGFR2+ mononuclear cells. These cells differentiated into an endothelial phenotype, expressed endothelial markers, and incorporated into neovessels at sites of ischemia (Asahara et al., 1997). EPCs provide both instructive (release of pro-angiogenic cytokines) and structural (vessel incorporation and stabilization) functions that contribute to the initiation of neo-angiogenesis. EPC populations can be characterized based on surface markers of freshly isolated cells, or they can be described by their in vitro characteristics once placed in culture. However, a major stumbling block to progress in the field has been the lack of consensus among investigators as to the optimal characterization of EPCs. This review intends to address the role of both EPC classes and evaluate how they interact in the setting of pathological angiogenesis. Since the EPCs may be responsible for turning on the "angiogenic switch," strategies have been employed to keep this switch in the "off" position for diseases like cancer, retinopathy, and wet AMD. The expectation is that EPCs will evolve into clinically useful prognostic and predictive tools in cancer and in ocular diseases associated with pathological neovascularization and that targeting this cell type is a key to successful management of patients suffering from diseases associated with pathological neovascularization.

KW - Diabetic retinopathy

KW - Endothelial progenitor cells

KW - Stem cells

UR - http://www.scopus.com/inward/record.url?scp=77952090934&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77952090934&partnerID=8YFLogxK

U2 - 10.1016/j.mvr.2010.02.011

DO - 10.1016/j.mvr.2010.02.011

M3 - Article

C2 - 20188747

AN - SCOPUS:77952090934

VL - 79

SP - 207

EP - 216

JO - Microvascular Research

JF - Microvascular Research

SN - 0026-2862

IS - 3

ER -